AlphAIalphai — Financial news for AI agents
rttnews.comJUN 124 min read$NVS

Novartis' Rhapsido Shows Promise In Chronic Inducible Urticaria

Novartis said late-breaking Phase 3 RemIND trial data for Rhapsido (remibrutinib) at the EAACI Congress met primary endpoints in chronic inducible urticaria subtypes: symptomatic dermographism, cold urticaria, and cholinergic urticaria. Complete responses at week 12 were 29.3%, 56.3%, and 29.3% vs 14–16% placebo. Novartis submitted a supplemental NDA to the FDA for symptomatic dermographism and plans further filings in 2026.

Original reporting
rttnews.com
Published Jun 12, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 4:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Novartis' Rhapsido Shows Promise In Chronic Inducible Urticaria — source image
Source · rttnews.com
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

Meeting primary endpoints with early and sustained responses supports label expansion prospects; supplemental NDA submission is the key near-term regulatory milestone mentioned.

02

Market read

Traders get a concrete clinical catalyst (Phase 3 endpoint success with subtype-specific response rates) plus a regulatory action (supplemental NDA submission) that can re-rate probability-weighted outcomes.

03

What to watch

Traders may discount the signal until full dataset, safety profile, and FDA interaction/CMC details for the supplemental NDA are available.

Relevance 8/10Novelty 8/10Timing: late-breaking Phase 3 data at EAACI Congress (published today)

Background

Rhapsido (remibrutinib) is already approved for chronic spontaneous urticaria; RemIND is evaluating it in chronic inducible urticaria subtypes.

Company-level read

Ticker impact

$NVSBullishMedium confidence
Context

Novartis reported late-breaking Phase 3 RemIND data showing Rhapsido met primary endpoints in chronic inducible urticaria and plans FDA supplemental NDA.

Expected impact

Bias toward upside as traders price in higher probability of FDA acceptance/approval for symptomatic dermographism and follow-on global filings.

Evidence & confidence

The article provides specific endpoint success rates by subtype and states a supplemental NDA submission to the FDA, which is a concrete regulatory pathway catalyst.

Market effects

Sector

Strengthens the targeted-therapy narrative in chronic inducible urticaria and may increase competitive attention on BTK inhibitors in immuno-dermatology.

Regional

Primarily US-focused via stated supplemental NDA to the FDA; global filings planned for 2026.

Global

EAACI Congress readout can influence international trial/payer expectations and competitor positioning across major markets.

Counterpoint

What could challenge this read

Endpoint success in a Phase 3 congress report may not fully de-risk FDA review; efficacy by subtype and safety/tolerability details are not provided here.

Key entities

  • company
    Novartis

    Sponsor of the RemIND Phase 3 trial and submitter of a supplemental NDA to the FDA for symptomatic dermographism.

  • drug
    Rhapsido (remibrutinib)

    Selective oral BTK inhibitor being evaluated for chronic inducible urticaria.

  • regulator
    FDA

    Receives a supplemental NDA submission for one CIndU subtype per the article.

Read at source← All news

Related articles

JUL 17
$NVSMedAI 8/10

Fabhalta gains full FDA approval for proteinuria reduction in IgA nephropathy

According to a Novartis press release, the FDA granted traditional approval to iptacopan (Fabhalta) for adults with primary IgA nephropathy at risk of progression. The drug had accelerated approval in Aug 2024. The company cites APPLAUSE-IgAN trial results, including a 3.02 mL/min/1.73 m2 per year eGFR slope difference and 48% slower decline vs placebo.

healio.com4 min
JUL 17
$NVSMedAI 9/10

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Novartis (NYSE:NVS)

The FDA granted traditional approval to Novartis (NYSE:NVS) for Fabhalta (iptacopan), an oral treatment for adults with primary IgA nephropathy at high risk of progression. The drug is intended to slow kidney function decline and delay dialysis or transplant needs. FDA approval was based on the Phase 3 APPLAUSE-IgAN trial, where annualized eGFR decline was -3.0 vs -5.7 mL/min/1.73 m2/yr with placebo.

benzinga.com4 min
JUL 17
$NVSMedAI 9/10

Fabhalta Earns Full FDA Approval to Slow Kidney Decline in Primary IgAN

The FDA granted traditional approval to Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy at risk of progression, based on long-term results from the phase 3 APPLAUSE-IgAN trial (N=477). Iptacopan 200 mg twice daily vs placebo reduced annualized eGFR decline (-3.0 vs -5.7 mL/min/1.73m2 per year) and lowered kidney failure events (21.4% vs 33.5%, HR 0.6).

empr.com4 min
JUL 17
$NVSMedAI 8/10

FDA grants traditional approval to Novartis’ Fabhalta for IgAN

The FDA granted Novartis traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy at risk of progression. Based on the Phase III APPLAUSE-IgAN trial, mean annual eGFR decline was -3.0 vs -5.7 mL/min/1.73m²/yr vs placebo over two years. Approval includes REMS due to serious infection risk.

yahoo.com4 min
JUL 17
$NVSHighAI 9/10

Novartis Wins FDA Approval For Fabhalta In IgA Nephropathy

Novartis said the U.S. FDA granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy at risk of progression, based on the Phase 3 APPLAUSE-IgAN trial. Novartis reported Q1 2026 Fabhalta sales of $169 million, up 103% at constant currency. NVS stock closed at $152.73.

rttnews.com4 min